化学性质:
|              规格  |                          5mg 25mg  |         
|              CAS  |                          1714146-59-4  |         
|              别名  |                          
  |         
|              化学名  |                          N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-5-ethyl-4-oxo-7-(3-(trifluoromethyl)phenyl)-4,5-dihydrothieno[3,2-c]pyridine-2-carboximidamide  |         
|              分子式  |                          C22H22F3N3O3S2  |         
|              分子量  |                          497.55  |         
|              溶解度  |                          DMF: 30 mg/mL,DMF:PBS(pH 7.2)(1:1): 0.5 mg/mL,DMSO: 25 mg/mL  |         
|              储存条件  |                          Store at -20°C  |         
|              General tips  |                          For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.  |         
|              Shipping Condition  |                          Evaluation sample solution : ship with blue ice  |         
产品描述:                                                                                                             
pIC50: 7.3
I-BRD9 is a BRD9 inhibitor.
BRD9 is identified as a bromodomain containing protein forming a small sub-branch of the bromodomain family tree. Human BRD9 has a single bromodomain and contains five isoforms which are produced by alternative splicing.
In vitro: In previous study, the I-BRD9 development was driven by iterative medicinal chemistry, using structure based design to result in nanomolar potency at BRD9, over 700-fold selectivity against the BET family as well as more than 70-fold to a panel of 34 bromodomains. In Kasumi-1 cells, I-BRD9 could downregulate DUSP6, CLEC1, SAMSN1 and FES genes. Moreover, I-BRD9 was used to expore genes regulated by BRD9 in Kasumi-1 cells involved in immune response and oncology pathways. In addition, when BRD4 was used as a representative member of the BET family for initial selectivity screening, I-BRD9 was found to have a pIC50 of 5.3 against this protein. I-BRD9 thus represented the first available selective tool compound to investigate the cellular phenotype of the inhibition of BRD9 bromodomain [1].
In vivo: So far, there is no animal in vivo data reported for I-BRD9.
Clinical trial: Up to now, I-BRD9 is still in the preclinical development stage.
特别提醒:
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
标签:I-BRD9
联系人:高小姐
手 机:13585831301
Q Q:3004967995
座 机:021-59541103
传 真:021-60443211
地 址:上海嘉定区嘉罗公路1661